Re Korean Reimbursement Code

Deltex Medical Group PLC
10 April 2002

10 April 2002

       Deltex Medical Group plc ('Deltex Medical' / 'Group' / 'Company')

                 CARDIOQ AWARDED REIMBURSEMENT CODING IN KOREA

Chichester, UK - Further to its announcement on 14 January 2002, Deltex Medical
(AIM: DEMG), the AIM listed haemodynamic monitoring company, is pleased to
announce that the Korean Government has now published its reimbursement rate to
be used to fund hospitals using Deltex's CardioQTM and related products in the
treatment of cardiac and cardiothoracic patients.

This reimbursement approval signals a significant step forward in the
development of Korea as a market for the CardioQTM, one which the Group believes
has considerable potential for growth.

Commenting, Nigel Keen, Deltex Medical's Chairman, said:

'We regard Korea as a market with considerable potential and we have received
considerable interest to date from the medical community.  Working closely with
our distribution partner, E-Wha International Inc., we are now very well
positioned to develop the excellent opportunities in the Korean market.'

Korea represents a large and growing healthcare market*, with over 46 million
inhabitants.  In 1998, healthcare expenditure was over US$13.9 billion (5% of
Korea's Gross Domestic Production) and, in 2000, the Korean market for medical
equipment and supplies was valued at US$960 million.

* source - Medistat



                                     -ends-

For further information, please contact:

Deltex Medical Group, plc
[phone]
Nigel Keen, Chairman and Chief Executive
Ewan Phillips, Chief Financial Officer

Financial Dynamics
[phone]
Stephanie Highett/Sarah Mehanna

Notes to Editors

Deltex primarily develops, assembles and markets a cardiac function monitor and
therapy guidance device, the CardioQTM ('CardioQTM'/'Monitor'). The CardioQTM
incorporates the Company's proprietary software and a narrow, easy-to-use,
minimally invasive, disposable oesophageal probe, used for transmitting and
receiving an ultra-sound ('Doppler') signal. By using this Doppler technology,
the CardioQTM provides clinicians with an early warning on the haemodynamic
condition of critically ill patients. This continuous, real-time monitoring
facilitates the administration of fluids or drugs in a timely fashion and
provides an provides an immediate assessment of their impact.

There are already over 600 CardioQTMs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 75 clinical publications on the use of the CardioQ
TM which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQTM works over a variety of types of operation

  • shown that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The Company is also currently developing a number of new products:-

  • A multi-patient probe for use in specific circumstances in certain markets

  • The SupraQTM - a monitor based on the CardioQTM technology but using a
    completely non-invasive probe; the prototype is being prepared for clinical
    testing in the second half of 2002

  • The NeuroQTM - a monitor designed to measure blood flow in the brain; the
    new prototype is in preparation for clinical trials in the second half of
    2002.

The multi-patient probe for use in operating theatres in the UK will be launched
in July 2002.


                      This information is provided by RNS
            The company news service from the London Stock Exchange